Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.

Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C.

N Engl J Med. 2012 Oct 11;367(15):1417-27. doi: 10.1056/NEJMoa1115050. Erratum in: N Engl J Med. 2012 Nov;367(18):1768.

2.

Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma.

Creaney J, Dick IM, Robinson BW.

Curr Opin Pulm Med. 2015 Jul;21(4):352-6. doi: 10.1097/MCP.0000000000000167. Review.

PMID:
26016578
3.

Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.

Ren R, Yin P, Zhang Y, Zhou J, Zhou Y, Xu R, Lin H, Huang C.

Oncotarget. 2016 Dec 20;7(51):84851-84859. doi: 10.18632/oncotarget.12707. Review.

4.

Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.

Emri S, Ustündağ Y, Budak T, Karakoca Y, Ozdemir O.

Monaldi Arch Chest Dis. 1997 Aug;52(4):335-8. Review.

PMID:
9401361
5.

Soluble markers for diagnosis of malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Bruno R, Foddis R.

Biomark Med. 2011 Apr;5(2):261-73. doi: 10.2217/bmm.11.18. Review.

PMID:
21473730
6.

Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.

Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP.

J Clin Oncol. 2012 May 1;30(13):1541-9. doi: 10.1200/JCO.2011.39.6671. Epub 2012 Mar 12. Review.

7.

Current status of screening for malignant pleural mesothelioma.

Pass HI, Carbone M.

Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):97-104. doi: 10.1053/j.semtcvs.2009.06.007. Review.

PMID:
19822280
8.

An autopsy case of malignant pleural mesothelioma associated with nephrotic syndrome.

Suzuki S, Toyoshima M, Nihashi F, Tsukui H, Baba S, Sugimura H, Suda T.

Intern Med. 2014;53(3):243-6. Review.

9.

The established and future biomarkers of malignant pleural mesothelioma.

Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD.

Cancer Treat Rev. 2015 Jun;41(6):486-95. doi: 10.1016/j.ctrv.2015.05.001. Epub 2015 May 8. Review.

PMID:
25979846
10.

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I.

Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. Review.

11.

Pleural mesotheliomas--an analysis of 18 cases and review of the literature.

Taryle DA, Lakshminarayan S, Sahn SA.

Medicine (Baltimore). 1976 Mar;55(2):153-62. Review.

PMID:
768710
12.

Malignant mesothelioma of the pleura.

Pisani RJ, Colby TV, Williams DE.

Mayo Clin Proc. 1988 Dec;63(12):1234-44. Review.

PMID:
3059081
13.

Imaging of the pleura.

Müller NL.

Radiology. 1993 Feb;186(2):297-309. Review. No abstract available.

PMID:
8421723
14.

CT and MR imaging in the evaluation of pleural masses.

Heelan RT.

Chest Surg Clin N Am. 1994 Aug;4(3):431-50. Review.

PMID:
7953477
15.

Systematic review and meta-analysis of vascular endothelial growth factor as a biomarker for malignant pleural effusions.

Fafliora E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG.

Physiol Rep. 2016 Dec;4(24). pii: e12978. doi: 10.14814/phy2.12978. Review.

16.

Translational advances in pleural malignancies.

Stathopoulos GT.

Respirology. 2011 Jan;16(1):53-63. doi: 10.1111/j.1440-1843.2010.01890.x. Review.

PMID:
21044230
17.

[Value of Cell Block in the Diagnosis of Malignant Pleural Effusion].

Cheng F, Wang Q, Zhong D.

Zhongguo Fei Ai Za Zhi. 2015 Oct 20;18(10):652-5. doi: 10.3779/j.issn.1009-3419.2015.10.09. Review. Chinese.

18.

[Malignant pleural mesothelioma--histopathological classification, staging and microscopic diagnosis].

Ewa SW, Renata L.

Pneumonol Alergol Pol. 2005;73(3):285-91. Review. Polish. No abstract available.

PMID:
16989168
19.

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Bruno R, Alì G, Fontanini G.

J Thorac Dis. 2018 Jan;10(Suppl 2):S342-S352. doi: 10.21037/jtd.2017.10.88. Review.

20.

Diagnosis and prognosis-review of biomarkers for mesothelioma.

Sun HH, Vaynblat A, Pass HI.

Ann Transl Med. 2017 Jun;5(11):244. doi: 10.21037/atm.2017.06.60. Review.

Supplemental Content

Support Center